Invention Grant
US07411054B2 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
失效
25869,25934,26335,50365,211117,38692,46508,16816,16839,49937,49931和49933分子及其用途
- Patent Title: 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
- Patent Title (中): 25869,25934,26335,50365,211117,38692,46508,16816,16839,49937,49931和49933分子及其用途
-
Application No.: US11445606Application Date: 2006-06-02
-
Publication No.: US07411054B2Publication Date: 2008-08-12
- Inventor: Rachel E. Meyers , Mark J. Williamson
- Applicant: Rachel E. Meyers , Mark J. Williamson
- Applicant Address: US MA Cambridge
- Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Main IPC: C12N15/54
- IPC: C12N15/54 ; C12N9/12 ; C12N15/74 ; C12N15/79

Abstract:
The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Public/Granted literature
Information query
IPC分类: